share_log

HC Wainwright & Co. Downgrades Surface Oncology to Neutral, Announces $5 Price Target

Benzinga ·  Jun 20, 2023 18:09

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Surface Oncology (NASDAQ:SURF) from Buy to Neutral and announces $5 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment